



WST97AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/048,046 Confirmation No.: 2775
Applicant : Halazonetis et al.
Filed : January 24, 2002
TC/A.U. : 1642
Examiner : M. Davis
Customer No. : 00270
Title : COMPOSITIONS AND METHODS TO ENHANCE SENSITIVITY
OF CANCER CELLS TO MITOTIC STRESS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and after the receipt of a first Office Action. Therefore, the fee of \$180.00 is enclosed.

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: October 29, 2004
Signature Kelly A. Karstaedt
Name Kelly A. Karstaedt

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.


REMARKS

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818



Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/048,046
				Filing Date	January 24, 2002
				First Named Inventor	Halazonetis et al.
				Group Art Unit	1642
				Examiner Name	M. Davis
Sheet	1	of	1	Attorney Docket Number	WST97AUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BV	HALAZONETIS, T.D., "Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer", <i>DNA Repair (Amst)</i> . Aug.-Sept. 2004 3(8-9):1057-1062	
	BW	HUYEN et al., "Structural differences in the DNA binding domains of human p53 and its <i>C. elegans</i> ortholog Cep-1", <i>Structure (Camb)</i> . July 2004 12(7):1237-1243	
	BX	MARIATOS et al., "Inactivating mutations targeting the <i>chfr</i> mitotic checkpoint gene in human lung cancer", <i>Cancer Res</i> . November 1, 2003 63(21): 7185-7189	
	BY	MOCHAN et al., "53BP1, an activator of ATM in response to DNA damage", <i>DNA Repair (Amst)</i> . Aug.-Sept. 2004 3(8-9):945-952	
	BZ	MOCHAN et al., "53BP1 and NFBID/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage", <i>Cancer Res</i> . December 15, 2003 63(24): 8586-8591	
	CR	STAVRIDIS et al., "p53 and stress in the ER", <i>Genes Dev</i> . February 1, 2004 18(3):241-244	
	CS	VENERE et al., "Chk2 leaves the PML depot", <i>Nature Cell Biol</i> . November 2002 4(11):E255-E256	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.